Anne Li September 16th, 2017 email@example.com
On September 23rd, 2016, The U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab). The new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients: TRAPS, HIDS/MKD, FMF. All three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain. There are no previously approved therapies for TRAPS or HIDS/MKD.
See original article at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522283.htm